LGALS3 and breast carcinoma: A post hoc analysis by Wanderley et al., 2022 [271], of breast cancer patients included in the CECCY trial, revealed that Gal-3 levels remained unchanged among the patients with dropped LVEF of least 10% (n = 26; 10.4 ng/mL (8.5, 12.6)) compared to the patients with no change in LVEF (n = 148; 10.3 ng/mL (7.6, 12.5)) at 6 months after initiation of anthracycline treatment (p = 0.85).